Skip to main content

Table 1 Baseline and Demographic Characteristics of the Survey Populationa

From: Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

Characteristic Total (n = 253) EM (n = 119) CM (n = 134) Quarterly (n = 131) Monthly (n = 122)
Mean (SD) age, years 45.5 (11.6) 46.9 (12.3) 45.2 (11.0) 47.3 (10.9) 44.7 (12.2)
Mean (SD) age at migraine diagnosis, years 23.5 (9.4) 24.5 (10.4) 22.5 (8.4) 24.6 (10.0) 22.3 (8.7)
Sex, n (%)
 Female 224 (88.5) 104 (87.4) 120 (89.6) 120 (91.6) 104 (85.2)
 Male 29 (11.5) 15 (12.6) 14 (10.4) 11 (8.4) 18 (14.8)
Race, n (%)b
 Caucasian 210 (83.0) 99 (83.2) 111 (82.8) 103 (78.6) 107 (87.7)
 Black/African American 24 (9.5) 13 (10.9) 11 (8.2) 16 (12.2) 8 (6.6)
 Asian/Pacific Islander 8 (3.2) 2 (1.7) 6 (4.5) 4 (3.1) 4 (3.3)
 Native American 1 (0.4) 1 (0.8) 0 1 (0.8) 0
 Other 7 (2.8) 4 (3.4) 3 (2.2) 4 (3.1) 3 (2.5)
  1. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, SD standard deviation
  2. aBaseline and demographic data are shown for the 253 eligible patients who completed the survey. Data are not shown for the 49 patients who consented but did not meet the study criteria (ie, took a CGRP pathway–targeted treatment after completing the extension study) and were excluded from participation in the survey study
  3. b3 patients did not provide a response